Drug intelligence / Profile preview

Compound 3034

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

**Compound 3034** is a small molecule inhibitor of SerpinB9 (Sb9). It functions by relieving Sb9's inhibition on Granzyme B (GzmB), thereby enhancing immune-mediated apoptosis in tumor cells. This mechanism is crucial for its role in cancer immunotherapy, particularly effective in melanoma and other cancers like breast, lung, and kidney cancers[1][4].

Targets

SERPINB9 (Serpin family B member 9)

Beyond the preview

Go deeper on Compound 3034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Compound 3034.

Explore the full profile